HK Stock Market Move | WHARF REIC (01997) surged over 30% in the afternoon, with a significant narrowing of mid-term losses and a 40% increase in dividends to 94 Hong Kong cents.
The stock price of Wharf Holdings Limited (01997) surged sharply in the afternoon, rising nearly 32% to HKD 34.82 at its peak.
WHARF REIC (01997) saw its stock price skyrocket in the afternoon, peaking at nearly a 32% increase to HK$34.82. As of the time of writing, it had risen 9.55% to HK$28.90, with a trading volume of HK$450 million.
In terms of news, WHARF REIC released its interim results for 2026, reporting revenue of HK$6.34 billion, a year-on-year decrease of 1.05%; the company's attributable loss to shareholders was HK$176 million, a year-on-year decrease of 92.69%; the loss per share was HK$0.06, and the company plans to distribute its first interim dividend of HK$0.94 per share, representing a year-on-year increase of 42% from HK$0.66 in the same period last year.
Additionally, considering the current earnings base and the debt situation, the group announced an increase in its dividend payout ratio from 65% of recurring core net earnings to 90%, indicating a 38% increase in the base dividend. In light of interest rate fluctuations and external environmental challenges, the group maintains a prudent approach to debt management. Net debt has been reduced to HK$29.2 billion, and the debt ratio has dropped to 15.9%, both reaching historic lows.
Related Articles

Zhenjiankang Medical (02697) has reached a strategic cooperation with the Tianjin Embodied Intelligence Innovation Center to jointly build an embodied intelligence medical industry ecosystem.

Zheshang: Improvement in supply and demand + self-sufficiency in fibers leads to better profitability in high-end box boards.
After overcoming regulatory setbacks, Moderna (MRNA.US) has finally received approval for its first mRNA flu vaccine. The commercialization prospects still need to be verified.
Zhenjiankang Medical (02697) has reached a strategic cooperation with the Tianjin Embodied Intelligence Innovation Center to jointly build an embodied intelligence medical industry ecosystem.

Zheshang: Improvement in supply and demand + self-sufficiency in fibers leads to better profitability in high-end box boards.

After overcoming regulatory setbacks, Moderna (MRNA.US) has finally received approval for its first mRNA flu vaccine. The commercialization prospects still need to be verified.
RECOMMEND





